Bright Minds Biosciences, Inc. (DRUG), a company focused on drug-resistant epilepsy, depression, and other central nervous system disorders, said on Tuesday that it has appointed Stephen D. Collins as Chief Medical Officer with immediate effect.
The company has also announced that Mark A. Smith will retire from his role as Acting CMO but will continue to serve in an advisory capacity.
Prior to joining Bright Minds, Collins simultaneously served as CEO of Biscayne Neurotherapeutics and CEO of Biscayne Pharmaceuticals, which was sold to Supernus Pharmaceuticals in 2018.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.